Every week, we have dozens of conversations with drug development experts from various corners of the industry. This helps us keep our fingers on the pulse of the industry, so we can identify the best talking points for you at our MicroSummits. This week's highlights were particularly enlightening: 👉 There's an ongoing debate about the shift of Cell Therapies to allogeneic approaches, particularly evident as the CART field moves in this direction. Currently, Gamida Cell's Omisirge stands out as the first FDA-approved allogeneic treatment in this evolving landscape. 👉 Have we overdone the multiplicity of combinations? Is there something to be said about going back to basics and not burning out modes of action in triplets, quadruplets, etc and rather reserve them for future development? 👉 We learned about the pivotal role of costimulatory molecules (costims) in elevating the efficacy of CAR-T therapies, indicating their significance as a next-generation concept within the field of CAR-T therapy. Interested in being a facilitator at one of our events? Get in touch! What we have coming up: 📅 The Blood Cancer Drug Development Summit (Oct 2023) 📅 Immuno-Oncology MicroSummit (August 22, 1pm Eastern) 📅 Liquid Biopsy MicroSummit (August 24, 1pm Eastern) Join the conversation! #CellTherapy #Biotech #Innovation #liquidbiopsy #immunooncology
MicroSummits’ Post
More Relevant Posts
-
Last chance to attend our Cell Engager session that everyone is raving about this summer! 🌟 Join the final Cell Engager Therapeutics Microsummit 🌟 🗓 Date & Time: September 18, 2024 | 1-2 PM Eastern / 10-11 AM Western Open Exclusively to Drug Developers: Learn and Connect with R&D leaders in a focused, virtual setting. What’s on the Agenda? 👉🏼 Innovative T-cell Engagers: Advancements in trispecific T-cell engagers and conditional co-stimulation are being developed to enhance efficacy and reduce side effects in oncology treatments. 👉🏼 Autoimmunity Solutions: Research is focusing on the precise engagement of T regulatory cells to better manage autoimmune diseases without exacerbating immune responses. 👉🏼 Technological Integration: The integration of machine learning and biomarker-driven strategies is refining the design and optimization of T-cell engagers, improving their therapeutic precision and effectiveness. Interactive Format & Networking: In just 55 minutes, experience lightning talks and engaging discussions fostering new connections. 🌐 Don’t Miss Out! Register below to join and network with industry leaders #cellengagers #TherapeuticInnovation #Biotech
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Brand New Microsummit Series Announced! 🌟 Join the Targeted Protein Degradation Microsummit 🌟 🗓 Date & Time: September 12, 2024 | 1-2 PM Eastern / 10-11 AM Pacific Open Exclusively to Drug Developers: Learn and Connect with R&D leaders in a focused, virtual setting. What’s on the Agenda? 👉🏼 Proximity Ligation Methods: Discover advanced techniques revealing new modes of action through protein complex studies. 👉🏼 Protein-Protein Interactions: Understand how meta-stable interactions underpin the design of effective protein degraders. 👉🏼 Intracellular Degradation: Explore methods for targeting “undruggable” proteins using recombinant BioPROTACs. And much more! Format & Networking: In just 55 minutes, enjoy lightning talks and personal discussions, leaving you with new connections and innovative ideas. 🌐 Don’t Miss Out! Register below to join and network with industry leaders. #TargetedProteinDegradation #TherapeuticInnovation #Biopharma #InducedProximity
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Exciting News - The date is set for the next chapter of our record-breaking Cell Engager series: 🌟 Join the Cell Engager Therapeutics Microsummit 🌟 🗓 Date & Time: August 21, 2024 | 1-2 PM Eastern / 10-11 AM Western Open Exclusively to Drug Developers: Learn and Connect with R&D leaders in a focused, virtual setting. What’s on the Agenda? 👉🏼 Biomarker Strategies: Explore essential biomarker strategies that enhance cell engager development. 👉🏼 MAIT Engagers for Enhanced Efficacy: Overcoming the limitations of classical T-cell engagers. 👉🏼 Future Directions: Discover cutting-edge research and applications. Interactive Format & Networking: In just 55 minutes, experience lightning talks and engaging discussions fostering new connections. 🌐 Don’t Miss Out! Register below to join and network with industry leaders #cellengagers #TherapeuticInnovation #Biotech
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Brand New Microsummit Announced! 🌟 Join the Cell Engager Therapeutics Microsummit 🌟 🗓 Date & Time: July 17, 2024 | 1-2 PM Eastern / 10-11 AM Western Open Exclusively to Drug Developers: Learn and Connect with R&D leaders in a focused, virtual setting. What’s on the Agenda? 👉🏼 Biomarker Strategies: Discover the most relevant biomarker strategies for optimal cell engager development. 👉🏼 TCR-Mimetic Impact: Understand the future impact of TCR-mimetic technologies on targeted cancer therapies. 👉🏼 Future Directions: Discover cutting-edge research and applications. Format & Networking: In just 55 minutes, enjoy lightning talks and personal discussions, leaving you with new connections and innovative ideas. 🌐 Don’t Miss Out! Register below to join and network with industry leaders. #CellEngagers #TherapeuticInnovation #Biopharma #CancerResearch
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Every week, we engage in insightful discussions with leading experts in drug development, enabling us to stay at the forefront of industry trends and identify key topics for our MicroSummits. In this week's discussions, we explored several groundbreaking advancements in the rapidly evolving domain of cell engager immunotherapy: 🎯 Macrophage Engagers: These novel agents harness the phagocytic activity of macrophages to target and eliminate tumor cells. By selectively engaging macrophages, these therapies show promise in overcoming resistance mechanisms in solid tumors, offering a targeted approach to cancer treatment. ☣️ NK Cell Engagers: NK cell engagers utilize the innate cytotoxic capabilities of NK cells to combat cancer. Recent studies highlight their versatility and efficacy across various malignancies. However, challenges such as NK cell exhaustion and maintaining prolonged activity remain critical areas for further research and development. 🔍 Gamma Delta T Cell Engagers: Emerging research indicates that gamma delta T cell engagers possess potent cytotoxicity and unique advantages over conventional alpha beta T cells. These agents demonstrate enhanced tumor-targeting capabilities and improved persistence. Despite their potential, the limited availability of gamma delta T cells poses a significant challenge. 🔄 Fusion Proteins: Fusion proteins represent a multifaceted approach to cancer therapy by integrating various functional domains into a single molecule. These proteins can interact with tumor antigens, immune cell receptors, and elements of the tumor microenvironment, resulting in diverse anti-tumor effects such as direct cell killing, immune activation, and checkpoint modulation. Are you interested in facilitating a discussion at one of our events? Let us know! #CellEngagers #TumorMicroenvironment #Immunomodulation #CellTherapy #bispecificantibodies
To view or add a comment, sign in
-
Join the Series Finale of our Bispecific Antibody Microsummit 🌟 Series Finale - June 20th is your last chance to experience a MicroSummit on the latest developments in bispecific antibody research and applications. 🗓 Date & Time: June 20, 2024 | 1-2 PM Eastern / 10-11 AM Western Open Exclusively to Drug Developers: Join a select group of R&D leaders for a focused exploration, all from the comfort of your desk. What’s on the Agenda? 👉🏼 Innovative Strategies in Early Discovery: Learn about the latest model-based approaches that are shaping the future of bispecific modalities. 👉🏼 Enhancing Antitumor Activity: Discover novel methods combining crucial cellular signals to boost therapeutic effectiveness. 👉🏼 Advances in Computational Design: Understand the role of AI and computational tools in developing next-generation biologics. Format & Networking: In just 55 minutes, experience lightning talks followed by personal discussions, ensuring you leave with 7 new connections and numerous innovative ideas. 🌐 Don’t Miss This Finale! Register below to take part and connect with industry leaders. #BispecificAntibodies #BiopharmaInnovation #Bispecifics #TherapeuticInnovation
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Join Our Grand Finale of the mRNA-Based Therapeutics Microsummit! 🌟 Series Finale on June 18th! It's your last chance this year to dive into the revolutionary world of mRNA-based therapeutics - all from the comfort of your desk! 🗓 Date & Time: June 18, 2024 | 1-2 PM Eastern / 10-11 AM Western What to Expect? 👉🏼 Pioneering mRNA Strategies: Engage with the latest advancements in mRNA technology for disease treatment and prevention. 👉🏼 AI in mRNA Therapeutics: Explore how artificial intelligence is propelling the design and efficacy of new therapies. 👉🏼 Regulatory Landscapes and Success Stories: Gain insights from experts on navigating the complex regulatory environment and achieving milestones in mRNA therapy development. 👉🏼 Networking with Industry Leaders: Connect with top minds and peers from across the biopharma sector. Make the Most of This Final Session: Don't miss this opportunity to expand your network and enhance your understanding of the transformative potential of mRNA-based therapeutics. 🌐 Ready to be Part of it? Secure your spot now and close out the series with us! #mRNATherapeutics #BiotechInnovation #mRNA #TherapeuticInnovation
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
🌟 Record-Breaking Microsummit! Our launch session in April set a new attendance record, with great feedback from 150+ drug developers. If you missed out, here's your next opportunity: 🚀 Join Our Next Session of the Bispecific Antibody Microsummit! 🗓 Unveiling Next-Generation Therapeutics: Dive deep into the frontier of bispecific antibody development and their transformative applications. All in one power-hour. What’s on the Agenda? 👉🏼 Neo-X-Prime Bispecific Antibodies: Uncover the latest in tumor targeting with CD40 agonists, offering unprecedented efficacy and precision in cancer therapy. 👉🏼 Towards Biologics by Design: Engage with the cutting-edge of multispecific protein therapeutics enhanced by computational optimization for sharper targeted treatments. 👉🏼 Biomarker-Driven Bispecific Design: Explore the critical role biomarkers play in crafting bispecific antibodies for personalized and potent therapeutic strategies. 👉🏼 Bispecifics Beyond Oncology: Expand your perspective with bispecific applications in non-oncology fields, promising new solutions for a diverse range of conditions. 🌐 Be Part of the Progress - Register with one click, below: #BispecificAntibodies #BiopharmaInnovation #Bispecifics #TherapeuticInnovation #BiologicsByDesign
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
🌟 Great Start to our mRNA-based Therapeutics series - Over 100 drug developers joined our first session in April. If you missed out, here’s another chance to get involved! 🚀 Join our Second Session of the Microsummit on mRNA-Based Therapeutics! 🗓 When? April 23, 2024 | 1-2 PM Eastern / 10-11 AM Western What’s in Store? 👉🏼Discover pioneering strategies in mRNA drug development for oncology and beyond. 👉🏼Explore cutting-edge advancements in AI for vaccine efficacy. 👉🏼Delve into regulatory insights and success stories in mRNA therapy development. 👉🏼Engage with leading minds from Biopharma companies large and small. Connect and Learn: 🌐 Ready to be inspired? Register below: #mRNATherapeutics #BiotechInnovation #mRNA #TherapeuticInnovation
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
Introducing our Bispecifics Microsummit! Unveiling Next-Generation Therapeutics: Join us for a focused exploration into the cutting-edge of bispecific antibody development and applications. Here's a sneak peek into our expert-led sessions: 👉🏼Neo-X-Prime Bispecific Antibodies: Discover the next generation of tumor targeting with CD40 agonists that promise enhanced efficacy and precision in cancer therapy. 👉🏼Towards Biologics by Design: Dive into the future of multispecific protein therapeutics through computational optimization, paving the way for more effective and targeted treatments. 👉🏼Biomarker-Driven Bispecific Design: Learn about the pivotal role of biomarkers in designing bispecific antibodies for more personalized and effective therapeutic strategies. 👉🏼Bispecifics Beyond Oncology: Explore the expanding horizon of bispecific applications in non-oncology fields, opening new avenues for treating a wide range of diseases. 📅 Join Us for an Intensive Exploration of Bispecific Therapeutics Don't miss this unique opportunity to engage with leading experts and advance your understanding of bispecific antibodies' transformative potential. All it takes is 55 minutes from the comfort of your desk! #BispecificAntibodies #BiopharmaInnovation #Bispecifics #TherapeuticInnovation #BiologicsByDesign
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in